NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Kodiak Sciences Inc. (KOD) Stock Analysis

Kodiak Sciences Inc. (KOD) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

KOD

$87.72

−$5.25 (−5.65%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare KOD with… →

KOD Key Statistics

As of Oct 21, 2026
Trading
Open
$91.14
Previous Close
$92.97
Day's Range
87.29–94.64
52-Week Range
15.83–104.00
Volume
942.90K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.04
Valuation
Market Cap
$5.51B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−4.19
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$229.97M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
62.85M
1-Year Return
+361.68%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
1.67M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, KOD closed at $87.72, +361.68% over 1 year.

Kodiak Sciences Inc. (KOD) has a market capitalization of $5.51B.

In fiscal 2025, KOD reported revenue of $0.00.

KOD Stock Return by Calendar Year

Kodiak Sciences Inc. (KOD) return since Oct 2018: what $10,000 became

1 year
$10,000 $46,168
+361.68%
5 years
$10,000 $7,739
−22.61%
Since Oct 2018
$10,000 $86,339
+763.39%

If you had invested $10,000 in Kodiak Sciences Inc. (KOD) at the close on October 4, 2018, the earliest close on record here, it would have been worth $86,339 at the close on October 21, 2026: +763.39% in total, +30.72% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+213.73%
2025+181.01%
2024+227.30%
2023−57.54%
2022−91.55%
2021−42.29%
2020+104.18%
2019+913.38%
2018 (partial year)−30.12%

As of October 21, 2026.

KOD Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$229.97M—
2024$0.00−$176.21M—
2023$0.00−$260.49M—
2022$0.00−$333.82M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$234.39M−$229.97M—
2024$0.00—−$186.85M−$176.21M—
2023$0.00—−$277.32M−$260.49M—
2022$0.00—−$341.38M−$333.82M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Kodiak Sciences Inc. (KOD) at $5.51B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 141.

KOD last closed at $87.72 on October 21, 2026. That is −$5.25 (−5.65%) against the previous close. The 52-week range on file runs from $15.83 to $104.00. The latest close sits 454.14% above that 52-week low.

Financial Health

In fiscal 2025, Kodiak Sciences Inc. reported revenue of $0.00. The same year closed with a net loss of $229.97M. Earnings per share on a trailing basis come to −4.19.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year total return is +361.68%. Measured over 5 years, that is −5.00% a year compounded. The reported beta is 2.04. Daily returns over the trailing 8 years annualize to a volatility of 120.61%.

Growth & Income

No dividend is on file for KOD.

The strongest complete calendar year on file is 2019 at +913.38%; the weakest is 2022 at −91.55%. Of the 7 complete calendar years on file, 4 finished higher. 2026 is still running; the total return is +213.73% year to date.

Peer Comparison

Kodiak Sciences Inc. (KOD) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Kodiak Sciences Inc. KOD $5.51B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Kodiak Sciences Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Kodiak Sciences Inc.

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Visit website →